

## Novel Concepts for Neurology and Medicine from the Interaction between Signalling Pathways Mediated by $\text{Ca}^{2+}$ and cAMP: An Intriguing History

Leandro BB<sup>\*</sup> and Afonso C

Department of Pharmacology, Escola Paulista de Medicina, Universidade Federal de São Paulo, Brazil

<sup>\*</sup>Corresponding author: Leandro BB, Department of Pharmacology, Escola Paulista de Medicina, Universidade Federal de São Paulo, Brazil, Tel: 55 11 5576-4973; E-mail: [leandric39@yahoo.com.br](mailto:leandric39@yahoo.com.br)

Received date: April 12, 2017; Accepted date: April 24, 2017; Published date: May 04, 2017

Copyright: © 2017 Leandro BB, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

### Abstract

It is now well-established that the signalling pathways mediated by  $\text{Ca}^{2+}$  and cAMP can interact ( $\text{Ca}^{2+}$ /cAMP signalling interaction), thus playing a vital role in cellular processes of mammals. In the neurology and medicine, it has opened novel opportunities for the development of pharmaceuticals more efficient, and safer, for treating neurodegenerative diseases. The solution for the so-called "calcium paradox" has been revealed 4 years ago, when we demonstrated the involvement of the  $\text{Ca}^{2+}$ /cAMP signalling interaction in this enigma. The "calcium paradox" emerged 4 decades ago, when numerous clinical studies have concluded that prescription of L-type  $\text{Ca}^{2+}$  channel blockers (CCBs) for hypertensive patients decreased arterial pressure, but produced stimulation of sympathetic hyperactivity. Indeed, initially these adverse effects of CCBs have been attributed to adjust reflex of arterial pressure, but this conclusion remained not completely satisfactory. The year of 2013 would change this history forever! Through an original experiment, we revealed that the "calcium paradox" phenomenon came from increased transmitter release from sympathetic neurons stimulated by CCBs due to its handling on the  $\text{Ca}^{2+}$ /cAMP signalling interaction. Then, the manipulation of  $\text{Ca}^{2+}$ /cAMP signalling interaction could improve therapeutic strategies for stimulating synaptic transmission compromised by transmitter release deficit, and attenuating death of neurons.

**Keywords:**  $\text{Ca}^{2+}$ /cAMP signalling interaction; Paradoxical effects produced by CCBs; Neurology

### Introduction

From the past years, it has been shown that the signalling pathways mediated by  $\text{Ca}^{2+}$  and cAMP can interact ( $\text{Ca}^{2+}$ /cAMP signalling interaction), thus playing a vital role in cellular processes of mammals. In the neurology and medicine, it could improve therapeutic strategies for stimulating synaptic transmission compromised by transmitter release deficit, and attenuating death of neurons.

It has been almost 4 years since we revealed the involvement of the  $\text{Ca}^{2+}$ /cAMP signalling interaction in the enigma of the so-called "calcium paradox". For understanding the "calcium paradox", we should return to the past. Indeed, the concept of stimulus-secretion to elucidate neurotransmitters release has been achieved from creative experiments made by Douglas, et al. [1]. By their concepts, in 1970's Baker and Knight [2] showed that an increase in the cytosolic  $\text{Ca}^{2+}$  concentration ( $[\text{Ca}^{2+}]_c$ ) is a fundamental requirement to start transmitter release. In addition, the unquestionable result showing a correlation between neurotransmitter release and elevation in  $[\text{Ca}^{2+}]_c$  came from the interesting experiments made by the Nobel laureate Erwin Neher [3]. Thus, by reducing extracellular  $\text{Ca}^{2+}$  through blocking  $\text{Ca}^{2+}$  channels, we should have a reducing in the neurotransmitter release. Nonetheless, many reports have demonstrated that L-type  $\text{Ca}^{2+}$  channel blockers (CCBs), in concentrations below 1  $\mu\text{mol/L}$ , could induce neurotransmitter release, a "paradox" [4-6]. In addition, many reports have demonstrated that cAMP enhances neurotransmitter release at several synapses in

autonomic nervous system of mammals [7]. Recently, we demonstrated that  $\text{Ca}^{2+}$ /cAMP signalling interaction is implicated in the modulation of transmitters release from sympathetic neurons and adrenal chromaffin cells [8-11].

The interaction between  $\text{Ca}^{2+}$  and cAMP signalling pathways as a classical concept: an intriguing history

It is well established that the interaction between  $\text{Ca}^{2+}$  and cAMP signalling pathways is as a vital cellular process in mammals [8-11]. This classical concept assumes that these signalling pathways virtually exist in all mammalian cells, modulated by adenylyl cyclases (ACs) and phosphodiesterases (PDEs) [8-11]. In addition, endoplasmic reticulum (ER)  $\text{Ca}^{2+}$  channels have particularly been a forefront for the interaction between  $\text{Ca}^{2+}$  and cAMP signalling pathways field, such as  $\text{Ca}^{2+}$  channels modulated by ryanodine receptors (RyR) [8-11]. We reinforced the idea that the interaction between  $\text{Ca}^{2+}$  and cAMP signalling pathways plays a fundamental participation in the modulation of neurotransmitter release from neurons and neuroendocrine cells [8-11]. Then, the interaction of  $\text{Ca}^{2+}$  and cAMP signalling pathways could be a new therapeutic goal for pharmaceuticals.

The interaction between  $\text{Ca}^{2+}$  and cAMP signalling pathways and neurology

The prescription of L-type CCBs in hypertensive patients has been reported to decrease arterial pressure, but also produces sympathetic hyperactivity [12]. Initially, these adverse effects of CCBs have been attributed to adjust reflex of arterial pressure, but this conclusion remained not completely satisfactory. The year of 2013 would change



- 4 Kreye VA, Luth JB (1975) Proceedings: verapamil-induced phasic contractions of the isolated rat vas deferens. *Naunyn-Schmiedeberg Arch Pharmacol* 287 Suppl: R43
- 5 French